cyrilzakka/clinical-trials huggingface dataset:
European Pathology Laboratories and COVID-19

The infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), notably when handling human samples, remains poorly understood, as well as the impact of the COVID-19 pandemic in routine clinical and molecular pathology practice, and for personal working in pathology laboratories. This study evaluates the consequences of the COVID-19 crisis in clinical and molecular pathology laboratories in Europe mostly those orientated for diagnosis of thoracic diseases.


Eligibility Criteria:
Inclusion Criteria:

* laboratories following the COVID-19 crisis
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.


Eligibility Criteria:
Inclusion Criteria:

* Confirmation of intent to receive radiotherapy for one of the following diagnoses:

  * Cervical cancer
  * Pancreatic cancer
* ECOG performance status ≤ 2
* At least 18 years old
* Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria:

* Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician
Artificial Intelligence in Dental Implant Planning

Artificial intelligence (AI) is revolutionizing the dentistry, offering new opportunities to improve the precision and efficiency of implantology. This study aims to evaluate the current evidence on the use of AI in implant planning assessment

The analysis was conducted through electronic search engines, using a combination of relevant keywords, including "artificial intelligence implantology," "AI implant planning," "AI dental implant," and "implantology artificial intelligence." Selected articles will carefully re-viewed to identify studies reporting data on the effectiveness of AI in implant planning.

Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent 3D or 2D radiological examinations for implant-prosthetic rehabilitation
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.

Researchers will measure the rate of hepatic and renal glucose production following dapagliflozin administration to determine the site of increase in EGP, liver versus kidney. Researchers will measure the rate of whole body glucose production with 3-3H-glucose (a form of radioactive glucose) and renal glucose production by renal vein catheterization in T2DM (type 2 diabetes mellitus) and in lean healthy NGT (normal glucose tolerance) individuals. Because the increase in EGP is associated with an increase in plasma glucagon concentration and renal glucose production is stated to be unresponsive to glucagon, the investigators anticipate that the liver will be responsible, in part, for the increase in EGP.

Eligibility Criteria:
Inclusion Criteria:

* 25-35 kg/m\^2
* Normal Glucose Tolerance subjects (24)
* Type 2 Diabetic Subjects (24)
* Diabetic subjects must be on a stable dose (more than 3 months) of monotherapy or combination therapy with metformin and/or a sulfonylurea
* Diabetic subjects must have HbA1c \<8.0%
* Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, blood chemistries, CBC (complete blood count), TSH (thyroid-stimulating hormone), T4 (thyroxine), EKG (electrocardiogram) and urinanalysis.
* Only subjects whose body weight has been stable (± 3 lbs) over the preceding three months and who do not participate in an excessively heavy exercise program will be included.

Exclusion Criteria:

* Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea) will be excluded.
* Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine \>1.4 females or \>1.5 males, or 24-hour urine albumin excretion \> 300 mg will be excluded.
Studies on Tumors of the Thyroid

Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer.

The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.

The purpose of this study is to gain knowledge and experience in the diagnosis and therapy of thyroid cancer using established best standard of care and new techniques and approaches as they are developed. Study subjects will include adults and children with thyroid nodules requiring diagnostic imaging and fine needle aspiration biopsy, surgery, radioiodine scanning or therapy, appropriate follow up, consisting of tumor markers monitoring and anatomical and functional imaging. The limitations and significance of serum thyroglobulin (Tg) measurement for diagnosing tumor recurrence will be assessed. The study will permit a continued evaluation of the risk/benefit ratio of already established methods of administering radioiodine therapy, including the impact of pre-treatment dosimetric calculations, individualizing treatment with radioiodine. Under this protocol, samples of benign nodules and cancer tissue specimens for research studies will be collected. Data and samples collected during routine clinical care will be used to address research questions utilizing a number of approaches including microscopy, immunohistochemistry, proteomics and molecular analysis. All research studies will relate to the diagnosis, natural history and therapy of thyroid tumors, regulation of thyroid function, and the effects of thyroid function on the body. Blood and urine specimens will be collected for research studies in both the hypothyroid and euthyroid state.

Eligibility Criteria:
* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Male or female, adults or children \>= 6 months+.
2. Patients with known or suspected thyroid nodules and/or thyroid cancer.
3. At risk family members of patients who have a genetic susceptibility to developing thyroid cancer.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma requiring intervention before thyroid cancer is addressed.
Risk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening

This study was designed to evaluate the effect of a targeted preoperative Methicillin-resistant Staphylococcus aureus (MRSA) detection by polymerase chain reaction (PCR) on either endogenous or exogenous postoperative MRSA infections in a high risk population undergoing gastroenterological surgery. The primary endpoint was to investigate whether the potentially high incidence of MRSA infections in patients with MRSA nasal colonization before surgery can be prevented with a PCR-based strategy. The second endpoint was to investigate the impact of acquisition of MRSA colonization after surgery on the occurrence of MRSA infections. Investigators hypothesize that postoperative MRSA infection is prevented by a targeted screening strategy in preoperative MRSA carrier, and there is limited effect in patients with postoperative MRSA acquisition.

Target screening for nasal carriage of MRSA by polymerase chain reaction (PCR) was performed before or on admission. In order to identify MRSA nasal acquisition while on the ward, all patients who were negative before surgery were re-screened every 7 days until discharge. The inclusion criteria for screening were patients undergoing inflammatory bowel disease surgery on ward A, and those undergoing major hepato-biliary-pancreatic surgery on ward B. Investigators classified enrolled patients into preoperative MRSA nasal carriage, postoperative nasal acquisition in patients who were negative for PCR assay before surgery, and non-nasal MRSA carriage during hospitalization. Development of postoperative infections caused by MRSA was assessed according to the nasal MRSA carriage status. MRSA infections rate was also compared between the 2-years of the intervention period and the previous 2-year control period on each ward.

Control measures in identified MRSA carriers consisted of contact precautions, antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA (application of 2% mupirocin ointment twice daily to nares for 5 days and a bath with 4% chlorhexidine daily for 3-5 days). Although contact precautions were used when caring for MRSA-colonized patients, isolation/cohorting was not routinely practiced.

Eligibility Criteria:
Inclusion Criteria:

* patients undergoing inflammatory bowel disease (IBD) surgery
* patients undergoing major hepato-biliary-pancreatic surgery

Exclusion Criteria:

* emergency surgery,
* age less than 18 years old
* known allergy to mupirocin or chlorhexidine.
The Best Way to Improve the Near Visual Acuity After ZXR00 IOL Implantation

The Best Way to Improve the Near Visual Acuity After ZXR00 IOL Implantation

ZXR00 intraocular lens is a new type of IOL that can achieve good continuous visual acuity. Its characteristic is to improve the distance and intermedia visual acuity and maintain good visual quality while sacrificing the near visual acuity. Previous studies report that there are mainly two ways to improve the near visual acuity of ZXR00：1.Bilateral implantation of ZXR00 with micromonovision. 2. Combined Implantation of ZXR00 and multifocal IOLs.This study aim to explore which is the best way to improve the near visual acuity after ZXR00 IOL implantation.

Eligibility Criteria:
Inclusion Criteria:

* Age of 18-80 years
* Cataract surgery is planned
* The operation was successful without any complications
* Implanted with ZXR00 IOLS or ZMB00 IOLs

Exclusion Criteria:

* The history of retinopathy or retinal surgery
* Irregular corneal astigmatism
* Regular corneal astigmatism of 1.00 diopter (D) or more
* Iris abnormalities
* Macular degeneration
* Neuro-ophthalmic disease
* The history of ocular inflammation
Oral Misoprostol Before Endometrial Biopsy

An endometrial biopsy involves a thin tube being passed through the cervix (opening of the uterus) to obtain a sample of the lining of the uterus. Sometimes there may be discomfort with this procedure especially if the cervix is not dilated or opened. Previous research has suggested that taking a drug called misoprostol may help the cervix to start to dilate or open. This study will see if misoprostol will help open the cervix for an endometrial biopsy, to lessen the discomfort and make the biopsy easier to perform.


Eligibility Criteria:
Inclusion Criteria:

* women 19 years and older
* planned endometrial biopsy

Exclusion Criteria:

* known hypersensitivity or allery to prostaglandins
* seizure disorder
* liver disease
* known abnormal liver function tests
* pregnancy
Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* Who are able and willing to give signed informed consent
* Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator.
* Who have up to 20% of body surface area (BSA) afflicted with plaques
* Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study.

Exclusion Criteria:

* Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity.
* Who are pregnant or lactating.
* Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease.
* Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
* Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study.
* Whose serum calcium levels exceed the upper limit of reference range
* Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of treatment.
* Who have been treated with systemic therapy within 30days of treatment.
* Who have treated with biologics within 5 half-lives of the biologics before the day of treatment
* Who have been treated with topical therapy within 14days before the day of treatment.
WATSU and Body Awareness

Body awareness (BA) is an essential factor for health and well-being. In 2021, the IOBA (Impact on Body Awareness) study was conducted at the Institute of Physical Medicine \& Rehabilitation at Kepler University Hospital. Thereby, the impact of massage and of gymnastics on BA in healthy individuals was surveyed. The protocol provides a solid basis for further research projects on BA. In the present study, the direct effect of a WATSU® (Shiatsu in Water) application on BA as well as on the state of health of healthy persons will be determined and BA will be further investigated.

In a randomized controlled study with 60 healthy adults in two groups (WATSU and control group), the use of the Awareness Body Chart (ABC) questionnaire and further German questionnaires (Short questionnaire on self-perception of the body, self-rating mood scale - revised) concerning body awareness and well-being should analyse the following hypothesis: There is a difference in the change of BA between the WATSU group and the control group. Before interventions demographic data and further questionnaires concerning health conditions of the participants (Simple Physical Activity Questionnaire, Short Form Health Survey, Brief Symptom Inventory, Like/Dislike Body Chart and additional questions) are administered. Correlations between BA and the results of these tests will be investigated too. All these analyses can provide innovative information about BA and be indicative in the use of physiotherapeutic measures.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* Signing of informed consent by participants and head of the study
* Understanding of German language in order to be able to follow a lecture and complete questionnaires

Exclusion Criteria:

* Current sick leave
* Pregnancy
* Acute physical or psychological complaints on the day of study participation
* Chronic illnesses / disabilities which contraindicate participation or make it difficult to use the therapy pool
* Current illnesses or injuries
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

Comparing ranibizumab and aflibercept in a treat and extend algorithm evaluating the number of needed injections over a 18 month period in patients with newly diagnosed CRVO.

Forty patients diagnosed with a new central retinal vein occlusion (CRVO) of a maximum duration of 6 months will be recruited to the study. Patients will be randomized 1:1 to treatment with aflibercept ot ranibizumab.

all patients will receive 3 initial monthly injections. There after injections will be given att every visit according to a treat and extend schedule. If no macular edema is seen on the Ocular coherent tomography (OCT) examination the next treatment will be after 6 weeks. If the macula is dry after 6 weeks a new injection is given and the next visit is scheduled for another 8 weeks. If edema is seen on the OCT after 8 weeks the time to next injection is reduced to 6 weeks. Patients cannot receive an injection more often than every 4 weeks. All patients will receive an injection at least every 12 weeks.

Primary outcome: the number of needed injections over a 18 month period comparing ranibizumab and aflibercept.

Secondary outcome: Change in visual acuity, change in macular thickness. A subgroup of patients will also be evaluated with OCT angiography. A possible relationship between the Visual acuity and the foveal avascular zone will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* CRVO - naive patients, disease duration maximum 12 months, Best corrected visual acuity : 23-73 letters (20/40 - 20/320), Macular edema \> 300 μm (Cirrus)

Exclusion Criteria:

* Neovascular Glaucoma Any previous treatment for CRVO. Intraocular surgery during the previous 3 months. Vascular retinopathy of other causes. Glaucoma with uncontrolled IOP (intra ocular pressure) Myocardial infarction or stroke during the last 3 months.
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC


Eligibility Criteria:
Inclusion Criteria:

1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;
2. Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT;
3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital;
4. Diagnosis time: November 1, 2014 to December 31 , 2017

Exclusion Criteria:

1. Disease progression during IMRT;
2. Previous malignancy or other concomitant malignant diseases;
3. The evaluation information of tumor efficacy can not be obtained;
4. Receive blind treatment in other clinical research.
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy (XRT).

Response will be assessed on the basis of the presence or absence of measurable lesion ≥ 1.4 x 1.4 cm (operationally defined as ≥ 2.0 cm2) by radiographic evaluation OR ≥ 1.0 cm in greatest diameter detected by palpation on physical exam

Eligibility Criteria:
INCLUSION CRITERIA

* Histologically confirmed low grade CD20+ B cell non-Hodgkin lymphoma (NHL) patients who have relapsed after chemotherapy or are chemotherapy resistant and have one or more sites of disease measuring more than 5 cm.
* The patients must have failed at least one chemotherapy regimen
* No anticancer treatment for three weeks prior to study initiation (six weeks if Rituximab, nitrosourea or Mitomycin C)
* Fully recovered from all toxicities associated with prior surgery, radiation, chemotherapy or immunotherapy
* An institutional review board- (IRB)-approved signed informed consent
* Age 19 years or older
* Expected survival of at least 6 months
* Prestudy Performance Status of 0, 1 or 2 according to the World Health Organization (WHO)
* Absolute neutrophil count (ANC) of at least 1,500/mm³
* Platelet count at least 100,000/mm³
* Hct \> 30%
* Hgb \> 9.0 gm
* Bilirubin ≤ 2.0
* Creatinine ≤ 2.0
* Bone marrow involvement with lymphoma less than 25% (bilateral bone marrow) within 6 weeks of enrollment
* Acceptable birth control method for men and women

EXCLUSION CRITERIA

* Disease progression within 3 months of last chemotherapy
* Prior myeloablative therapies with bone marrow transplantation or peripheral stem cell rescue
* Platelet count less than 100,000/mm³
* Hypocellular bone marrow (≤ 15% cellularity)
* Marked reduction in bone marrow precursors of one or more cell lines
* History of failed stem cell collection
* Prior treatment with fludarabine
* Prior radioimmunotherapy
* Presence of central nervous system (CNS) lymphoma
* HIV or AIDS-related lymphoma
* Evidence of myelodysplasia on bone marrow biopsy
* Abnormal bone marrow cytogenetics
* Patients who have received prior external beam radiation therapy to more than 25% of active bone marrow
* Patients who have received filgrastim
* Sargramostim therapy within 3 weeks prior to treatment
* Presence of human anti-mouse antibody (HAMA) reactivity in patients with prior exposure to murine antibodies or proteins
* Serious nonmalignant disease or infection, which, in the opinion of the investigator and/or sponsor, would compromise other protocol objectives
* Another primary malignancy (other than squamous cell and basal cell cancer of the skin, in situ carcinoma of the cervix, or treated prostate cancer with stable prostate-specific antigen, PSA) for which the patients has not been disease free for at least 3 years
* Major surgery, other than diagnostic surgery within 4 weeks
* Pleural effusion
* Pregnant
* Lactating
Change of Neural Network Indicators Through Narrative Treatment of PTSD in Torture Victims

Effective Treatment of PTSD involves talking about the traumatic event in detail.It is unclear how this process influences the sensory-specific trauma network (fear structure)in the traumatized person. The goal of the project is to test the hypothesis that treatment-facilitated recovery does not change the original fear structure but establishes an inhibitory mechanism that depends on verbal activity. An affective visual steady-state paradigm in magnetencephalography (MEG) using positive, aversive and neutral picture stimuli will be used to examine the spatial and temporal pattern of the processing of emotional stimuli. To examine the effects of treatment this paradigm will be used as outcome measure within a randomized controlled trial of Narrative Exposure Therapy and a waiting-list control condition for severely traumatized torture victims.


Eligibility Criteria:
Inclusion Criteria:

* experiences of organized violence/torture
* PTSD diagnosis

Exclusion Criteria:

* psychotic disorder
* neurological disease or seizures
* current drug/alcohol abuse
The Fibrin Patch Soft Tissue Study

The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.


Eligibility Criteria:
Inclusion Criteria:

* Subjects \>= 18 years of age, requiring non-emergent, open, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures
* Presence of an appropriate soft tissue Target Bleeding Site (TBS) as identified intraoperatively by the surgeon
* Subjects must be willing to participate in the study, and provide written informed consent

Exclusion Criteria:

* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure
* Subject with TBS within an actively infected field
* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine
* Subjects with known intolerance to blood products or to one of the components of the study product
* Subjects unwilling to receive blood products
* Subjects with immunodeficiency diseases (including known HIV)
* Subjects who are known, current alcohol and / or drug abusers
* Subjects who have participated in another investigational drug or device research study within 30 days of enrollment
* Female subjects who are pregnant or nursing